In Vivo Gene Therapy for Mucopolysaccharidosis Type III (Sanfilippo Syndrome): A New Treatment Horizon

Abstract excerpt

For most lysosomal storage diseases (LSDs), there is no cure. Gene therapy is an attractive tool for treatment of LSDs caused by deficiencies in secretable lysosomal enzymes, in which neither full restoration of normal enzymatic activity nor transduction of all cells of the affected organ is necessary. However, some LSDs, such as mucopolysaccharidosis type III (MPSIII) diseases or Sanfilippo syndrome, represent a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lysosomal Storage Disorders Research
• Share to Neurogenetic and Muscular Disorders Research
• Share to Virus-based gene therapy research